Biomarkers are not used only for diagnosis. Today, it is unthinkable to develop a new medication without simultaneous measurement of biomarkers to determine the efficacy, safety, and pharmacodynamics.

This project focuses on the search for biomarkers among alternative proteins. The collaborating researchers are professors Robert Day (prostate cancer), Tamas Fulop (Alzheimer's disease), Gilles Boire (polyrhumatoid arthritis) and Alan Cohen (biostatistics).

Mass spectrometry analyses are performed by PhenoSwitch Biosciences.